Temozolomide in Patients With Progressive or Recurrent Non-small Cell Lung Cancer
A Phase II Study of TEMOZOLOMIDE in Advanced Non-Small Cell Lung Cancer With and Without Brain Metastases
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Listed as NCT00003062, this PHASE2 trial focuses on Lung Cancer and remains completed. Sponsored by European Organisation for Research and Treatment of Cancer - EORTC, it has been updated 5 times since 1997, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Jul 1997
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- European Organisation for Research and Treatment of Cancer - EORTC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Amsterdam, Netherlands
- • Edinburgh, United Kingdom
- • Gdansk, Poland
- • Genoa, Italy
- • Johannesburg, South Africa